Contract Manufacturing Organizations (CMO)

Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

Fri, 23 Dec 2022 15:52:52 +0000

The Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

The pharmaceutical industry is going through significant changes that are altering its business models, according to our analyst. This represents one of the new opportunities for market participants in the global pharmaceutical contract manufacturing organisations. According to our analysis, the pharmaceutical contract manufacturing organisations (CMOs) market is estimated to be valued at US$1,04,396 million in 2022 and is projected to reach a market value of US$2,03,240 million by 2032.

Growing Demand and Acceptability of Biosimilars Can Be Seen as a Big Opportunity for Pharma CMOs
Growing demand and acceptability of biosimilars can be seen ...

$4,740.00

Pharmaceutical Contract Manufacturing Market Report 2022-2032

Fri, 21 Oct 2022 15:17:16 +0000

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth. ...

$5,056.00

PharmSource - CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance -- 2018 Edition

Wed, 30 Jan 2019 11:55:26 +0000

PharmSource - CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance - 2018 Edition, Edition analyzes the performance of the drug product CMO industry using NDA approvals as the primary indicator of performance. The report examines 118 drugs approved by the FDA Center for Drug Evaluation and Research (CDER) in 2017 along with four therapeutic drugs approved by the FDA Center for Biologics Evaluation and Research (CBER) under the BLA process (Table 4). NDA and BLA approvals include New Molecular Entities (NMEs), as well as new formulations of previously approved APIs. In addition, the report also includes drugs examined by the European Medicines Agency (EMA). The centralized procedure is mandatory for all New Active Substances (NASs), as well as biosimilar and certain generics. This report analyzes propensity to outsource by dosage form, sponsor type, nature of API, and special handling requirements. It includes information on products that have used formulation technologies such as amorphous solid dispersion (ASD), hot melt extrusion (HME), and jet milling. This year, we ...

$4,995.00